Biotech Firm Scribe Therapeutics Files for US Initial Public Offering

Biotechnology company Scribe Therapeutics has officially filed for an initial public offering (IPO) in the U.S., according to a registration statement submitted by the firm. The company plans to list its common stock on the Nasdaq Global Market under the proposed ticker symbol "SCTX".

Details of the Offering

The filing indicates the company's intent to go public but does not yet specify the number of shares to be offered or the target price range for the offering. These details were listed with placeholder values in the registration statement, a common practice in early-stage IPO filings.

Currently, there is no public market for Scribe Therapeutics' common stock. The successful completion of the IPO is contingent upon the company meeting all of the Nasdaq's listing requirements.

Underwriters and Market Context

Ad

A consortium of prominent financial institutions is managing the proposed offering. The lead underwriters listed in the filing are:

• Leerink Partners
• Goldman Sachs & Co. LLC
• Guggenheim Securities
• Wells Fargo Securities

This filing marks a significant step for Scribe Therapeutics as it seeks to access public capital markets to fund its operations and research. Investors will be watching for a subsequent filing that will provide concrete details on the offering's size and valuation.